뇌질환의 혁신, 뉴로벤티(NeuroVenti)

NEWS

Here's the news about NeuroVenti

Neuroventi executives and employees participated in the "autism r…

페이지 정보

조회 420회 작성일 23-11-20

본문

[Pharm News = Reporter Lee Seok-hoon] Neuroventy (CEO Shin Chan-young) announced on the 21st that its executives and employees participated in the Autism Race event held on the 18th as part of a campaign to improve awareness of autism disorders under the slogan "Different to Color."

(G)The event, which was held at the Peace Plaza of World Cup Park in Sangam-dong, Mapo-gu, Seoul, was organized by the Korea Autism Love Association in cooperation with the Seoul Metropolitan Government and Hana Bank to spread understanding and respect for Otism (autistic disorder).

As part of a campaign to improve awareness of autism disorders, it was first held in 2020 and has been held in the form of virtual run due to the spread of COVID-19, but this year, it will be held offline (virtual run parallel).

In particular, the event slogan "Different to Color" was created based on Park Eun-bin's acceptance speech, which won the grand prize in the drama category at the Baeksang Arts Awards in April, with the aim of hoping that our differences will come together to become the color of our society amid the recent spread of false hatred and prejudice against Otism in society.

The race was operated with two short-distance courses, a 4.2km course and a long-distance 10km course to celebrate April 2, World Autism Day, and as a campaign event, it was impressive to see them step together, even if they were somewhat slow, rather than competing with each other.

Neuroventy is currently working to develop an autism treatment, and executives and employees who felt socially responsible participated in the event voluntarily ahead of next year's phase 2 clinical trial.

Shin Chan-young, CEO of Neuroventy, said, "We will continue to do our best to develop treatments to create a good world where we do not worry even if we have autistic and developmental disabilities."

Source: Palm News (https://www.pharmnews.com )